Y. A. Hekster

3.0k total citations
116 papers, 2.3k citations indexed

About

Y. A. Hekster is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Y. A. Hekster has authored 116 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pediatrics, Perinatology and Child Health, 30 papers in Pharmacology and 24 papers in Psychiatry and Mental health. Recurrent topics in Y. A. Hekster's work include Pharmacological Effects and Toxicity Studies (32 papers), Antibiotics Pharmacokinetics and Efficacy (21 papers) and Epilepsy research and treatment (20 papers). Y. A. Hekster is often cited by papers focused on Pharmacological Effects and Toxicity Studies (32 papers), Antibiotics Pharmacokinetics and Efficacy (21 papers) and Epilepsy research and treatment (20 papers). Y. A. Hekster collaborates with scholars based in Netherlands, Japan and Australia. Y. A. Hekster's co-authors include T. B. Vree, A. M. Baars, David M. Burger, P.P. Koopmans, Eppo van der Kleijn, E.W. Wuis, A. Keyser, W.O. Renier, H. Meinardi and C.P.W.G.M. Verwey-van Wissen and has published in prestigious journals such as Neurology, Antimicrobial Agents and Chemotherapy and Journal of Chromatography A.

In The Last Decade

Y. A. Hekster

114 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y. A. Hekster Netherlands 27 621 609 538 407 330 116 2.3k
Ronald J. Sawchuk United States 29 543 0.9× 832 1.4× 1.2k 2.2× 367 0.9× 198 0.6× 93 3.3k
Indravadan H. Patel United States 27 381 0.6× 610 1.0× 917 1.7× 382 0.9× 152 0.5× 75 2.4k
Rashmi H. Barbhaiya United States 31 484 0.8× 363 0.6× 1.3k 2.5× 362 0.9× 212 0.6× 137 3.1k
Vincent Jullien France 31 1.1k 1.8× 744 1.2× 562 1.0× 325 0.8× 301 0.9× 125 3.3k
J. Heykants Belgium 22 650 1.0× 249 0.4× 263 0.5× 272 0.7× 500 1.5× 59 2.2k
Robert Woestenborghs Belgium 33 1.4k 2.3× 331 0.5× 439 0.8× 402 1.0× 672 2.0× 78 3.9k
Yechiel A. Hekster Netherlands 29 753 1.2× 790 1.3× 279 0.5× 547 1.3× 481 1.5× 73 2.7k
Petrie M. Rainey United States 31 771 1.2× 458 0.8× 192 0.4× 113 0.3× 240 0.7× 85 2.6k
D.J. Back United Kingdom 29 596 1.0× 475 0.8× 197 0.4× 137 0.3× 347 1.1× 80 2.2k
Chantal Csajka Switzerland 36 1.1k 1.8× 596 1.0× 698 1.3× 187 0.5× 522 1.6× 165 4.4k

Countries citing papers authored by Y. A. Hekster

Since Specialization
Citations

This map shows the geographic impact of Y. A. Hekster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. A. Hekster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. A. Hekster more than expected).

Fields of papers citing papers by Y. A. Hekster

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. A. Hekster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. A. Hekster. The network helps show where Y. A. Hekster may publish in the future.

Co-authorship network of co-authors of Y. A. Hekster

This figure shows the co-authorship network connecting the top 25 collaborators of Y. A. Hekster. A scholar is included among the top collaborators of Y. A. Hekster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. A. Hekster. Y. A. Hekster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gordijn, Bert, et al.. (2006). The Complexities of Ethical Evaluation of Genomics Research. HEC Forum. 18(1). 18–36. 9 indexed citations
2.
Aarnoutse, R.E., Jan Kleinnijenhuis, Peter J. Koopmans, et al.. (2005). Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clinical Pharmacology & Therapeutics. 78(6). 664–674. 49 indexed citations
3.
Belitser, Svetlana V., C. L. P. Deckers, A. Keyser, et al.. (2004). Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not. Pharmacoepidemiology and Drug Safety. 14(2). 107–112. 9 indexed citations
4.
Deckers, C. L. P., et al.. (2003). Selection Criteria for the Clinical Use of the Newer Antiepileptic Drugs. CNS Drugs. 17(6). 405–421. 27 indexed citations
5.
Koopmans, R.T.C.M., et al.. (2003). Increase in drug use after admission to Dutch nursing homes.. Pharmacy World & Science. 25(1). 30–34. 8 indexed citations
6.
Burger, D.M., et al.. (2000). Determination of nevirapine, an HIV-1 non nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high perfomance liquid chromatography. Journal of Chromatography B. 744. 64–71. 1 indexed citations
7.
Hugen, Patricia W. H., C.P.W.G.M. Verwey-van Wissen, David M. Burger, et al.. (1999). Simultaious determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.. Journal of Chromatography B. 727. 139–149. 65 indexed citations
8.
Burger, D.M., et al.. (1997). Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B. 703. 235–241. 30 indexed citations
9.
Lammers, M. W., Y. A. Hekster, A. Keyser, et al.. (1996). Use of antiepileptic drugs in a community-dwelling Dutch population. Neurology. 46(1). 62–67. 23 indexed citations
10.
Koopmans, R.T.C.M., et al.. (1996). Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses. Pharmacy World & Science. 18(1). 42–47. 10 indexed citations
12.
Vree, T.B., et al.. (1992). Capacity-limited renal glucuronidation of probenecid by humans. Pharmacy World & Science. 14(5). 325–331. 15 indexed citations
13.
Burger, David M., et al.. (1991). Omeprazole. Pharmacy World & Science. 13(5). 215–219. 1 indexed citations
14.
Hekster, Y. A., et al.. (1991). Clinimetrics and epilepsy care. Pharmacy World & Science. 13(4). 182–188. 18 indexed citations
15.
Keyser, A., et al.. (1990). Side-effects of drugs in epileptic patients. Pharmacy World & Science. 12(4). 145–150. 10 indexed citations
16.
Vree, T. B., et al.. (1989). Oxidation and O‐dealkylation of sulphamonomethoxine by the turtlePseudemys scripta elegans. Veterinary Quarterly. 11(3). 186–190. 6 indexed citations
17.
Vree, T. B., et al.. (1989). o‐Dealkylation and acetylation of sulfamethomidine by the snail Cepaea hortensis. Journal of Veterinary Pharmacology and Therapeutics. 12(3). 344–347. 4 indexed citations
18.
Vree, T. B., W. J. A. Wijnands, A. M. Baars, & Y. A. Hekster. (1988). Pharmacokinetics of nalidixic acid in man: Hydroxylation and glucuronidation. Pharmacy World & Science. 10(5). 193–199. 8 indexed citations
19.
Hekster, Y. A., et al.. (1979). ヒトの血しょうおよび尿中のニトロフラントイン(FuradantineR)およびヒドロキシメチルニトロフラントイン(UrfadynR)の高性能液体クロマトグラフィーによる定量. Journal of Chromatography A. 162(1). 110–116. 9 indexed citations
20.
Vree, T. B., Y. A. Hekster, A. M. Baars, & Eppo van der Kleijn. (1978). Rapid determination of amoxycillin (Clamoxyl®) and ampicillin (Penbritin®) in body fluids of many by means of high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 145(3). 496–501. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026